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Jan Albert Kuivenhoven, PHD,* James D. Otvos, PHD, Nicholas J. Wareham, MBBS, PHD,‡
Barbara A. Hutten, PHD,† John J. P. Kastelein, MD, PHD,* Kay-Tee Khaw, MBBCHIR,§
S. Matthijs Boekholdt, MD, PHD*
Amsterdam, the Netherlands; Cambridge, United Kingdom; and Raleigh, North Carolina
Objectives We assessed relations of low-density lipoprotein (LDL) particle number (LDL-P) and LDL particle size as mea-
sured by nuclear magnetic resonance spectroscopy with LDL cholesterol (LDL-C) and the risk of future coronary
artery disease (CAD).
Background Whereas LDL-C is an established risk factor for CAD, its discriminative power is limited. Measuring LDL-P and
size may have stronger associations with CAD than LDL-C.
Methods A nested case-control study was performed in the prospective EPIC (European Prospective Investigation into
Cancer and Nutrition)-Norfolk study, which comprises 25,663 subjects. Cases (n  1,003) were individuals who
developed CAD during 6 year follow-up. Control subjects (n  1,885) were matched for age, gender, and enroll-
ment time. Odds ratios (ORs) for future CAD were calculated, and we also evaluated whether LDL-P could im-
prove the Framingham risk score (FRS) to predict CAD.
Results In univariate analyses, LDL-P (OR 2.00, 95% confidence interval [CI] 1.58 to 2.59) and non-high-density lipoprotein
cholesterol (non–HDL-C) (OR 2.14, 95% CI 1.69 to 2.69) were more closely associated with CAD than LDL-C (OR 1.73,
95% CI 1.37 to 2.18). The additional value of LDL-P was lost after adjustment for HDL-C and triglyceride levels.
Whereas LDL size was inversely related to CAD (OR 0.60, 95% CI 0.47 to 0.76), this relation was abolished upon ad-
justment for LDL-P. In a model adjusted for the FRS, LDL-P retained its association with CAD (p for trend 0.02).
Conclusions In this large study of individuals with moderately elevated LDL-C, LDL-P was related to CAD on top of FRS
as well as after adjusting for LDL-C. The additional value of LDL-P was comparable to non–HDL-C, and it
was abolished after adjusting for triglycerides and HDL-C. (J Am Coll Cardiol 2007;49:547–53) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.043m
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Hhe causal role of low-density lipoprotein (LDL) particles
n the pathogenesis of coronary artery disease (CAD) is well
stablished, as is the clinical benefit of lowering LDL in
igh-risk patients. Hence, low-density lipoprotein-
holesterol (LDL-C) lowering is the principal target in
ardiovascular preventive strategies (1). Low-density li-
oprotein cholesterol content is used as a parameter to
stimate LDL-associated CAD risk. More recently, assess-
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s a more reliable method reflecting atherogenicity of the
DL fraction (2). Since the cholesterol content per LDL
article exhibits large inter-individual variation due to
ifferences in particle size as well as relative content of
holesterol ester and triglycerides in the particle core, the
nformation provided by LDL-C and low-density
ipoprotein-particle number (LDL-P) is not equivalent (3).
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LDL-P and LDL Size in the EPIC-Norfolk Study February 6, 2007:547–53Individuals with the same level of
LDL-C may have higher or
lower numbers of LDL particles
and, as a result, may differ in
terms of absolute CAD risk.
Prospective studies, in which
LDL particle concentration was
estimated by apolipoprotein B
(apoB) levels, have underscored
stronger associations between
LDL-P and CAD risk compared
with LDL-C, particularly in sub-
jects with normal LDL-C con-
centration (4,5). In addition, the
size of LDL particles may also
contribute to the atherogenicity
of LDL-C (6,7). Thus, at a given
level of LDL-C, individuals with
small LDL particles have greater
atherosclerotic risk than those
with large-size LDL (8,9).
Lipoprotein particle analysis
y nuclear magnetic resonance (NMR) spectroscopy is a
elatively new method by which both LDL-P and LDL
article size can be efficiently measured (10). We evaluated
he associations between LDL-P and LDL size, in com-
arison with LDL-C and non–high-density lipoprotein
holesterol (non–HDL-C) as traditional markers, and risk of
uture CAD in apparently healthy men and women enrolled in
large prospective cohort with moderately elevated LDL-C.
ince LDL-P and LDL size are closely related to traditional
ipid factors such as HDL-C and triglycerides, we performed
ultivariable analyses to assess independency of the correla-
ions. We also assessed clinical usefulness of these novel
arameters by determining their effect on the discriminative
ccuracy of the Framingham risk score (FRS).
ethods
e performed a nested case-control study among partici-
ants of the EPIC (European Prospective Investigation into
ancer and Nutrition)-Norfolk study, a prospective popu-
ation study of 25,663 men and women aged between 45
nd 79 years, resident in Norfolk, United Kingdom, who
ompleted a baseline questionnaire survey and attended a
linic visit (11). Participants were recruited from age-gender
egisters of general practices in Norfolk as part of the
0-country collaborative EPIC study designed to investigate
ietary and other determinants of cancer. Additional data
ere obtained in the EPIC-Norfolk study to enable the
ssessment of determinants of other diseases.
The design and methods of the study have been described
n detail (11). In short, eligible participants were recruited
y mail. At the baseline survey between 1993 and 1997,
articipants completed a detailed health and lifestyle ques-
Abbreviations
and Acronyms
apoB  apolipoprotein B
BMI  body mass index
CAD  coronary artery
disease
CI  confidence interval
FRS  Framingham risk
score
HDL-C  high-density
lipoprotein cholesterol
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
LDL-P  low-density
lipoprotein-particle number
NMR  nuclear magnetic
resonance
OR  odds ratioionnaire. Non-fasting blood was taken by vein puncture rnto plain and citrate bottles. Blood samples were processed
or assay at the Department of Clinical Biochemistry,
niversity of Cambridge, or stored at 80°C. All individ-
als were flagged for death certification at the United
ingdom Office of National Statistics, with vital status
scertained for the entire cohort. In addition, participants
dmitted to hospital were identified using their unique
ational Health Service number by data linkage with
NCORE (East Norfolk Health Authority) database. Cor-
nary artery disease was defined as codes 410-414 according
o the International Classification of Diseases-9th revision.
articipants were identified as having CAD during
ollow-up if they had a hospital admission and/or died with
AD as underlying cause. We report results with follow-up
p to January 2003, an average of about 6 years. The study
as approved by the Norwich District Health Authority
thics Committee, and all participants gave signed in-
ormed consent.
articipants. We excluded all individuals who reported a
istory of heart attack or stroke at the baseline clinic visit.
one of the cases or control subjects was on statin treat-
ent. Cases were individuals who developed a fatal or
on-fatal CAD during follow-up. For each case, 2 control
ubjects matched for gender, age (within 5 years), and time
f enrollment (within 3 months) were identified who had
emained free of CAD during follow-up.
MR spectroscopy. Lipoprotein subclass particle concen-
rations and average size of LDL particles were measured by
roton NMR spectroscopy (LipoScience, Inc., Raleigh,
orth Carolina) as previously described (10). Particle con-
entrations of lipoprotein subclasses of different size were
btained directly from the measured amplitudes of their
pectroscopically distinct lipid methyl group NMR signals.
he following LDL subclasses were defined: intermediate-
ensity lipoprotein (IDL) (23 to 27 nm), large LDL (21.2
o 23 nm), and small LDL (18 to 21.2 nm). Low-density
ipoprotein subclass particle concentrations are given in
nits of nmol/l. Summation of the LDL subclass levels
rovides total LDL (including intermediate-density li-
oprotein) particle concentrations. Weighted-average LDL
article sizes (in nm diameter units) are computed as the
um of the diameter of each subclass multiplied by its
elative mass percentage as estimated from the amplitude of
ts methyl NMR signal. Low-density lipoprotein subclass
istributions determined by NMR and gradient gel electro-
horesis are highly correlated (12). Low-density lipopro-
ein subclass diameters, which are consistent with elec-
ron microscopy data (13), are uniformly 5 nm smaller
han those estimated by gradient gel electrophoresis.
iochemical analyses. Serum levels of total cholesterol,
DL-C, and triglycerides were measured with the RA
000 (Bayer Diagnostics, Basingstoke, United Kingdom),
nd LDL-C levels were calculated with the Friedewald
ormula (14). Nuclear magnetic resonance analysis was
erformed on stored serum samples that were analyzed in
andom order to avoid systemic bias. Researchers and
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February 6, 2007:547–53 LDL-P and LDL Size in the EPIC-Norfolk Studyaboratory personnel were blinded to identifiable informa-
ion, and could identify samples by number only.
tatistical analysis. Baseline characteristics were compared
etween cases and controls taking into account the match-
ng. A mixed effect model was used for continuous variables,
nd conditional logistic regression was used for categoric
ariables. Because triglyceride levels had a skewed distribu-
ion, values were log-transformed before being used as
ontinuous variables in statistical analyses.
Spearman correlation coefficients and corresponding
values were calculated to assess associations between the
arious biomarkers and established continuous CAD risk
actors. To assess the strength of association between a risk
actor and the occurrence of CAD, we calculated odds ratios
ORs) and corresponding 95% confidence intervals (CIs) by
onditional logistic regression analysis, taking into account
atching for gender, age, and enrollment time. The ORs
ere calculated per quartile of each risk factor, with the first
uartile as the referent group. P values represent significance
or linearity across the ORs for the 4 quartiles of each risk
actor. To compare the individual strengths of disease
ssociation of LDL-P, non–HDL-C, LDL-C, HDL-C,
nd triglycerides, we calculated ORs for future CAD per
uartile of each variable in separate models adjusted for
moking (yes/no) and systolic blood pressure. Since our
bjective was to determine relations of lipids/lipoproteins
ith CAD, we did not adjust additionally for body mass
ndex (BMI) and diabetes, 2 lipid-altering risk factors.
ultivariable models were also examined to determine how
elations of each variable were affected by adjustment for the
ther lipid/lipoprotein variables.
Baseline Characteristics of Coronary ArteryDisease Cases and Matched Control Subjects
Table 1 Baseline Characteristics of CoronarDisease Cases and Matched Contro
Control Subjects
Male gender, % (n) 63.2 (1,19
Age, yrs 65
Diabetes, % (n) 1.6 (30)
Smoking, % (n) 8.3 (155)
BMI, kg/m2 26.2
Systolic blood pressure, mm Hg 139
Diastolic blood pressure, mm Hg 84
Chemical lipid measures
Total cholesterol, mmol/l 6.2 (5.5–
HDL cholesterol, mmol/l 1.3 (1.1–
LDL cholesterol, mmol/l 4.0 (3.4–
Triglycerides, mmol/l 1.6 (1.1–
Non-HDL cholesterol, mmol/l 4.8 (4.1–
NMR LDL particle measures
LDL particle number, nmol/l 1,525 (1,27
IDL, nmol/l 36 (14–6
Large LDL, nmol/l 572 (448–
Small LDL, nmol/l 885 (637–
LDL size, nm 21.1 (20.7
Data are presented as mean  SD, percentage (n), or median (inter
observations than the indicated number of subjects. Triglyceride levelBMI  body mass index; HDL  high-density lipoprotein; IDL  intermedia
magnetic resonance.We further assessed the relation of LDL-P and non–
DL-C with future CAD using a model that included the
RS. We calculated this score using a previously reported
lgorithm (15) based on age, gender, levels of total and
DL cholesterol, systolic and diastolic blood pressure,
iabetes, and smoking and categorized subjects into 3
roups: low (10%), intermediate (10% to 20%), or high
20%) risk. The ORs for future CAD were calculated
er quartile of the risk factor, adjusting for the FRS
ategory.
Statistical analyses were performed using SPSS software
version 12.0.1, SPSS Inc., Chicago, Illinois). A p value
0.05 was considered to indicate statistical significance.
esults
aseline characteristics. We identified 1,003 participants
ho were apparently healthy at baseline and developed
AD during follow-up. A total of 882 cases were matched
o 2 controls each, whereas the remaining 121 cases could be
atched to 1 control only, giving a total number of 1,885
ontrols. Baseline characteristics of cases and controls are
isted in Table 1. As expected, cases were more likely to be
mokers and diabetic subjects, and to have a higher blood
ressure and BMI than control subjects. Levels of total
holesterol, LDL-C, non–HDL-C, and triglycerides were
ignificantly higher in cases than in control subjects,
hereas HDL-C levels were significantly lower (p 0.0001
or each). Baseline LDL-P was higher in cases com-
ared with control subjects (p 0.0001). Levels of the large
DL subclass were not different, but cases had more IDL
ery
jects
1,885) Cases (n  1,003) p Value
63.9 (641) Matched
65 8 Matched
6.1 (61) 0.0001
15.7 (157) 0.0001
27.3 3.9 0.0001
144 19 0.0001
86 12 0.0001
6.4 (5.6–7.2) 0.0001
1.2 (1.0–1.8) 0.0001
4.2 (3.6–4.9) 0.0001
1.8 (1.3–2.6) 0.0001
5.2 (4.4–5.9) 0.0001
2) 1,640 (1,383–1,955) 0.0001
43 (19–78) 0.003
568 (427–708) 0.6
) 999 (747–1,330) 0.0001
21.0 (20.1–21.4) 0.002
range). Means, percentages, and medians may be based on fewer
log-transformed before analysis.y Art
l Sub
(n 
2)
8
3.4
18
11
6.9)
1.6)
4.7)
2.2)
5.6)
8–1,81
6)
704)
1,190
–21.5)
quartile
s werete-density lipoprotein; LDL  low-density lipoprotein; NMR  nuclear
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LDL-P and LDL Size in the EPIC-Norfolk Study February 6, 2007:547–53nd small LDL particles. Thus, the increased LDL-C in
ases is attributable mainly to increased cholesterol in small
DL. The average LDL particle size was smaller in cases
han control subjects.
ssociations of LDL measures with other CAD risk
actors. As shown in Table 2, LDL size was inversely
orrelated with LDL-P (r  0.58), but not with LDL-C
r  0.01). We identified a strong inverse relation of LDL
ize with triglyceride levels (r  0.53) and BMI (r 
0.19) and a positive correlation with HDL-C (r  0.54).
oth LDL-C and LDL-P were strongly interrelated (r 
.63), but both parameters had markedly different associa-
ions with HDL-C and triglycerides. Whereas LDL-C was
nly weakly associated with HDL-C (r  0.03) and
riglyceride levels (r  0.18), LDL-P was more strongly
orrelated with HDL-C (r  0.29) and triglycerides (r 
.55). Non–HDL-C was strongly correlated with LDL-P
pearman Correlationo fficie ts Betwee Measured Variables*
Table 2 Spearman CorrelationCoefficients Between Measured Variables*
Non-HDL
Cholesterol
LDL
Cholesterol
LDL Particle
Number LDL Size
LDL cholesterol 0.94
LDL particle number 0.76 0.63
LDL size 0.18 0.01† 0.58
Total cholesterol 0.94 0.93 0.65
HDL cholesterol 0.16 0.03‡ 0.29 0.54
Triglycerides 0.47 0.18 0.55 0.53
BMI 0.11 0.02§ 0.14 0.19
p  0.0001 for comparison unless otherwise indicated; †p  0.6; ‡p  0.09; §p  0.2.
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Odds Ratios for Future Coronary Artery DiseaseLipid/Lipoprotein Variable in Univariable and Mu
Table 3 Odds Ratios for Future Coronary ArtLipid/Lipoprotein Variable in Univar
1 2
Univariable models
LDL cholesterol 1.00 1.37 (1.09–1.73)
LDL particle number 1.00 1.23 (0.97–1.56)
HDL cholesterol 1.00 0.76 (0.60–0.95)
Triglycerides 1.00 1.27 (1.00–1.62)
Non-HDL cholesterol 1.00 1.31 (1.04–1.66)
Multivariable models
LDL cholesterol 1.00 1.26 (0.99–1.60)
HDL cholesterol 1.00 0.83 (0.66–1.04)
Triglycerides 1.00 1.12 (0.88–1.43)
LDL particle number 1.00 1.13 (0.89–1.44)
HDL cholesterol 1.00 0.86 (0.68–1.09)
Triglycerides 1.00 1.11 (0.87–1.42)
Non-HDL cholesterol 1.00 1.13 (0.88–1.44)
HDL cholesterol 1.00 0.83 (0.66–1.05)
Triglycerides 1.00 1.08 (0.85–1.39)
*Odds ratios (95% confidence intervals) were calculated by conditio
enrollment time and adjusted additionally for smoking and systolic blo
a separate model. Multivariable models examined each variable in
variables. †p for linear trend.
Abbreviations as in Table 2.r  0.76) and triglycerides (r  0.47), and inversely
orrelated with HDL-C (r  0.16) and LDL size (r 
0.18).
DL-P, traditional lipid risk factors, and risk for future
AD. Shown in the upper panel of Table 3 are the
nivariate ORs for future CAD associated with increasing
uartiles of non–HDL-C, LDL-C, LDL-P, HDL-C, and
riglycerides. The 5 lipid/lipoprotein measures exhibited
omparable strengths of association with CAD, with ORs
iffering approximately 2-fold comparing the highest and
owest quartiles. The magnitude of the predictive value of
DL-P and non–HDL-C were greater than that of
DL-C. Comparing the highest to lowest quartile, the OR
or LDL-P was 2.00 (95% CI 1.58 to 2.59) and 2.14 (95%
I 1.69 to 2.69) for non–HDL-C versus 1.73 (95% CI 1.37
o 2.18) for LDL-C.
The lower panels of Table 3 show the results of multi-
ariate analyses in which each lipid/lipoprotein variable was
djusted for the other 2 parameters to assess the indepen-
ence of their mutual relations with CAD. The associations
f both LDL-C and LDL-P with CAD were attenuated
fter adjustment for HDL-C and triglycerides, whereas
ttenuation was more pronounced for LDL-P than for
DL-C (4th quartile ORs reduced from 2.00 to 1.37 for
DL-P vs. 1.73 to 1.55 for LDL-C). Similarly, relations of
DL-C and triglycerides with CAD were attenuated more
y adjustment for LDL-P than LDL-C.
oncordance/discordance between LDL-C and LDL-P.
n a conditional logistic regression model that included both
arameters and corrected for smoking and systolic blood
uartile ofri ble Models*
isease by Quartile of
and Multivariable Models*
uartiles
p Value†3 4
1.38 (1.09–1.74) 1.73 (1.37–2.18) 0.0001
1.48 (1.17–1.87) 2.00 (1.58–2.59) 0.0001
0.60 (0.48–0.75) 0.50 (0.39–0.64) 0.0001
1.50 (1.20–1.88) 2.01 (1.61–2.51) 0.0001
1.57 (1.25–1.97) 2.14 (1.69–2.69) 0.0001
1.27 (1.00–1.61) 1.55 (1.22–1.96) 0.001
0.71 (0.56–0.89) 0.66 (0.50–0.87) 0.001
1.22 (0.96–1.54) 1.52 (1.19–1.95) 0.001
1.21 (0.94–1.54) 1.37 (1.04–1.83) 0.02
0.74 (0.59–0.94) 0.70 (0.53–0.92) 0.005
1.19 (0.93–1.51) 1.36 (1.04–1.79) 0.03
1.26 (0.99–1.62) 1.63 (1.26–2.11) 0.0001
0.71 (0.56–0.90) 0.66 (0.50–0.87) 0.001
1.13 (0.88–1.43) 1.30 (0.99–1.70) 0.06
istic regression, taking into account matching for gender, age, and
ssure. Univariable models examined each lipid/lipoprotein variable in
l adjusted for the other 2 lipid/lipoprotein variables as continuousby Qltiva
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February 6, 2007:547–53 LDL-P and LDL Size in the EPIC-Norfolk Studyressure, LDL-C was no longer statistically significantly
ssociated with future CAD (Table 4). The LDL-P, how-
ver, remained a significant risk factor, such that subjects in
he highest quartile had an OR of 1.78 (95% CI, 1.34 to
.37; p  0.0001 for linearity) (Table 4).
DL size and risk for future CAD. Table 5 shows the
Rs for future CAD associated with increasing quartiles of
DL size adjusted for smoking and systolic blood pressure,
ith and without additional adjustment for the potentially
onfounding inverse correlation of LDL size with LDL-P.
ithout adjustment for LDL-P, there was a significant
elation of smaller LDL size with CAD, with an OR for
ndividuals in the highest quartile compared with those in
he lowest quartile of 0.60 (95% CI 0.47 to 0.76). However,
pon adjustment for LDL-P, the relation of LDL size with
AD was greatly attenuated and was no longer significant.
DL-P and the FRS. The results in Table 6 indicate that
DL-P and non–HDL-C retain a similar association with
uture CAD after accounting for the FRS (OR of 1.34 and
.38, respectively, in the highest vs. lowest quartile).
iscussion
easurements of LDL-P and LDL size have the potential
o improve coronary disease risk assessment as well as
ecisions about LDL treatment intensity, since they account
or aspects of lipid atherogenicity that are incompletely
eflected by values of LDL-C. In this large prospective
ase-control study, we show that LDL-P and non–HDL-C
ere more closely associated with the occurrence of future
AD than levels of LDL-C. Upon adjusting for HDL-C
nd triglyceride levels, the predictive capacity of LDL-P was
omparable to that of LDL-C. Whereas LDL size was
elated to CAD risk, this relationship was abolished after
djusting for LDL-P. Both LDL-P and non–HDL-C had
Odds Ratios for Future Coronary Artery Diseaseby Quartile o LDL-C and LDL-P, Both Enter d In
Table 4 Odds Ratios for Future Coronary Artby Quartile of LDL-C and LDL-P, Bot
LDL Siz
1 2
LDL-C 1.00 1.23 (0.97–1.57)
LDL-P 1.00 1.18 (0.93–1.51)
*Odds ratios (95% confidence intervals) were calculated by conditiona
linear trend.
LDL-C  low-density lipoprotein cholesterol; LDL-P  low-density lip
Odds Ratios for Future Coronary Artery DiseaseQuartile of LDL Size, With a d Without Adjustme
Table 5 Odds Ratios for Future Coronary ArtQuartile of LDL Size, With and With
1 2
Range (nm) <20.6 20.7–
Unadjusted for LDL particle number 1.00 0.77 (0.6
Adjusted for LDL particle number 1.00 0.92 (0.7*Odds ratios (95% confidence intervals) were calculated by conditional logistic
without additional adjustment for low-density lipoprotein (LDL) particle numbncremental value on top of the FRS in multivariate analy-
es. Overall, these findings do not support routine use of
DL-P for CAD risk assessment in primary prevention
etting.
DL-P and risk for future CAD. The cholesterol content
f LDL particles, which can create discordance between
evels of LDL-C and LDL-P, is mainly influenced by
holesterol ester transfer protein activity, which is enhanced
nder circumstances of hypertriglyceridemia (8). This has 2
mportant consequences. First, transfer of cholesteryl ester
rom HDL particles to apoB-containing lipoproteins causes
ow HDL-C levels. Second, cholesterol depletion and
riglyceride enrichment of LDL particles facilitates the
ormation of small dense LDL particles (3,8). As a result,
DL-C levels generally underestimate the number of LDL
articles in individuals with elevated triglycerides, as clearly
llustrated in the Framingham Study (2,3). Discordance
etween LDL-C and LDL-P is also a feature of diabetic
atients (2,16) and the number of metabolic syndrome
omponents (2,17). Our data in the EPIC-Norfolk study
howing that triglyceride and HDL-C levels are much more
trongly correlated with LDL-P than LDL-C are in agree-
ent with these findings. Accordingly, it was not unex-
ected that the relation of LDL-P with CAD risk was to be
eakened more than that of LDL-C by multivariate ad-
ustment for triglycerides and HDL-C. Conversely, adjust-
ng for LDL-P weakened relations of CAD with triglycer-
des and HDL-C, suggesting that some of the risk associated
ith these non-LDL risk factors may actually stem from
levations of LDL-P not reflected by levels of LDL-C.
We found a moderate degree of discordance between
DL-C and LDL-P in our study population. While the
ource of this excess risk may not be due entirely to the
levated LDL-P, since those with discordantly high LDL-P
e Model*
isease
ered Into One Model*
tile
p Value†3 4
.88–1.45) 1.22 (0.92–1.61) 0.3
.08–1.79) 1.78 (1.34–2.37) 0.0001
c regression adjusted for smoking and systolic blood pressure; †p for
n particle number.
r LDL Particle Number*
isease by
djustment for LDL Particle Number*
LDL Size Quartile
p Value†
3 4
21.1–21.4 >21.4
7) 0.76 (0.60–0.95) 0.60 (0.47–0.76) 0.0001
6) 0.99 (0.77–1.28) 0.86 (0.65–1.15) 0.5to On
ery D
h Ent
e Quar
1.13 (0
1.39 (1
l logistibynt fo
ery D
out A
21.0
2–0.9
2–1.1regression adjusted for smoking and systolic blood pressure, with and
er; †p for linear trend.
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s biologically plausible that LDL-P makes a contribution.
urrent understanding of the pathophysiology of athero-
clerotic vascular disease is that LDL particles are active
articipants from the time they enter the artery wall, are
etained in the intima by binding to extracellular matrix,
ecome chemically modified by oxidation, and are subse-
uently ingested by macrophages to create foam cells and
ncreased plaque burden (2,4).
Despite the finding that LDL-P predicted CAD inde-
endently of the FRS, our results, showing a loss of
iscriminative power of LDL-P over LDL-C when
DL-C and triglyceride levels are accounted for, do not
rgue for the routine implementation of LDL-P assessment
or CAD risk assessment. Low-density lipoprotein choles-
erol particle number may, however, play a useful role in
atient management by helping judge the adequacy of LDL
owering therapy, particularly among those with elevated
riglycerides and reduced HDL-C. Such a role has been
roposed for apoB (4,5), and both non–HDL-C and apoB
ave been put forward as secondary treatment targets after
DL-C goals have been achieved (1,4). In fact, data
upporting LDL-P as an alternative treatment target has
ained support from clinical intervention studies showing
hat on-treatment levels of apoB or NMR-measured
DL-P were more reliable indicators of residual CAD risk
han on-treatment LDL-C (2,4,5,18,19).
DL size and risk for future CAD. Small LDL size is
nother factor associated with high triglycerides, low
DL-C, obesity, insulin resistance, diabetes, and metabolic
yndrome (6–9). Our finding of a relation between smaller
DL size and greater CAD risk is consistent with previous
tudies reporting that small LDL particles have higher
therogenic potential than large LDL particles (8,9). How-
ver, upon adjustment for LDL-P, the relationship of LDL
ize with CAD was abolished. This result is consistent with
ndings in the Multi-Ethnic Study of Atherosclerosis indi-
ating that NMR-measured numbers of small and large LDL
articles are related similarly to carotid atherosclerosis (20).
on–HDL-C and risk for future CAD. The present
ndings confirm that non–HDL-C is a better predictor of
AD than LDL-C (21,22). Previous studies have also
ound that the number of most atherogenic lipoprotein
articles, as measured by apoB, were more strongly related
Odds Ratios for Future Coronary Artery DiseaseAfter T k ng Into Account the Framingham Risk
Table 6 Odds Ratios for Future Coronary ArtAfter Taking Into Account the Fram
1 2
LDL cholesterol 1.00 1.17 (0.93–1.48)
LDL particle number 1.00 1.10 (0.86–1.39)
Non-HDL cholesterol 1.00 0.98 (0.73–1.32)
*Odds ratios were calculated by conditional logistic regression, with adj
trend.
Abbreviations as in Table 2.o CAD risk than was non–HDL-C (21,22). In the present rtudy, we show that the association of LDL-P with CAD is
lmost equal to that of non–HDL-C. The fact that apoB
aptures all atherogenic apoB particles (including very
ow-density lipoprotein and LDL), whereas LDL-P only
easures LDL particles, may have contributed to this
istinction. There has been an intense debate concerning
linical relevance of measuring particle numbers (apoB/
DL-P) and/or cholesterol content of the particles (non–
DL-C). In the present study, we observed that both
DL-P as well as non–HDL-C conferred predictive value
n top of the FRS. Since the association between LDL-P
nd CAD was equal to that of non–HDL-C, the present
ndings do not advocate routine use of LDL-P in CAD risk
ssessment. The potential value of LDL-P measurement for
onitoring patients on lipid-lowering medication needs to
e addressed in separate intervention trials.
tudy limitations. Our study has several limitations. The
tudy population was relatively elderly, which may limit the
eneralizability of our results. Case-control differences in
AD among older populations are more weakly related to
ipoprotein levels than in younger populations because many
f the control subjects have extensive subclinical disease, yet
ave not experienced a coronary event (23). Low-density
ipoprotein cholesterol levels in the study population were
lso considerably higher than in the general U.S. popu-
ation, with a mean LDL-C value in the EPIC-Norfolk
tudy corresponding to the 80th percentile of Framing-
am subjects of similar age and gender (24). Coronary
rtery disease events in our study were ascertained
hrough death certification and hospital admission data,
hich may lead both to under ascertainment and to
isclassification of cases. Previous validation studies in
his cohort, however, indicate high specificity of such case
scertainment (25).
In conclusion, in this large cohort of apparently healthy men
nd women, LDL-P and non–HDL-C were more closely
ssociated than LDL cholesterol with the occurrence of future
AD. After adjustment for HDL-C and triglycerides,
DL-P was no longer more predictive than LDL-C. These
ndings do not support routine use of LDL-P in CAD risk
ssessment strategies in primary prevention strategies. How-
ver, recognition that patients with low HDL-C and/or high
riglycerides often have elevated numbers of LDL particles
ithout having elevated LDL-C may enable their LDL-
e*
isease
m Risk Score*
artiles
p Value†3 4
.09 (0.86–1.39) 1.24 (0.97–1.58) 0.15
.22 (0.96–1.54) 1.34 (1.03–1.73) 0.02
.03 (0.76–1.38) 1.38 (1.01–1.90) 0.04
t for risk categories based on the Framingham risk score; †p for linearScor
ery D
ingha
Qu
1
1
1
ustmenelated CAD risk to be managed more effectively.
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